[1] Younossi ZM,Koenig AB,Abdelatif D,et al. Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence,incidence,and outcomes. Hepatology,2016,64:73-84.
[2] Fan JG,Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol,2009,50（1）:204-210.
[3] Golden-Mason LM,McMahan R,Cheng L,et al. Group 2 innate lymphoid cells（ILC2s） are altered in fatty liver disease. Hepatology,2016,64 （S1）:751A.
[4] McGettigan BR,McMahan H,Rosen R. RNA-seq of hepatic macrophages isolated from murine NASH identifies diverse roles for tissue-resident and infiltrating macrophages in disease pathogenesis. Hepatology,2016,64（S1）:127A.
[5] Zhou D,Pan Q,Zhang RN,et al. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by affecting GLP-1 and gut microbiota. Hepatology,2016,64（S1）:769A.
[6] Alkhouri N,Grove D,Mohamad B,et al. The effects of gut microbiota and the flavin mono-oxygenase enzyme 3（FMO3） on choline bioavailability in nonalcoholic fatty liver disease. Hepatology,2016,64（S1）:775A.
[7] Touhidul Islam SM,Chedister GR,Lench JH,et al. Saturated fat causes non-alcoholic steatohepatitis through the shifting of the gut microbiota to a higher endotoxemic profile. Hepatology,2016,64 （S1）:772A.
[8] Wang B,Baker SS,Liu WS,et al. Retinoic acid as a factor in the pathogenesis of NAFLD. Hepatology,2016,64（S1）:805A.
[9] Miyake N,Nakamoto R,Amiya T,et al. Roles of CC chemokine receptor 9 in the progression of murine non-alcoholic steatohepatitis. Hepatology,2016,64（S1）:790A.
[10] Kleiner DE,Brunt EM,Belt PH,et al. Diagnostic pattern and disease activity are related to disease progression and regression in nonalcoholic fatty liver disease. Hepatology,2016,64（S1）:19A.
[11] Fan JG,Chen GF,Ji D,et al. Long-term disease progression and prevalence of metabolic syndrome in chronic hepatitis B patients with comorbid nonalcoholic fatty liver disease. Hepatology,2016,64（S1）:538A.
[12] Roberts KK,Pathirana IN,Paredes AH,et al. Prospective comparison to liver biopsy of VCTE/CAP,MRE,PDFF,and multiparametric MRI for predicting degree of steatosis and diagnosis of NASH. Hepatology,2016,64（S1）:22A.
[13] Dinani RA,Toor JA. Transient elastography in combination with clinical markers（BARD score,FIB-4,NFS） can be useful in predicting the presence or absence of advanced fibrosis in patients with non alcoholic fatty liver disease. Hepatology,2016,64（S1）:560A.
[14] Massie VC,Sreedhar VH. Identification of early transformations and biochemical changes in patients with NASH by Fourier transform infrared spectroscopic imaging. Hepatology,2016,64 （S1）:553A.
[15] Kobayashi N,Kumada T,Toyoda H,et al. Evaluation of non-invasive markers for the diagnosis of nonalcoholic steatohepatitis. Hepatology,2016,64（S1）:593A.
[16] Shoji H,Yoshio S,Mano Y,et al. Interleukin-34 as a fibroblast-
derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatology,2016,64（S1）:544A.
[17] Alonso C,Puri P,Martinez-Arranz I,et al. Metabolomics in a liquid biopsy provides a noninvasive comprehensive NAFLD-
diagnostic tool. Hepatology,2016,64（S1）:20A.
[18] Perez-Cormenzana M,García C,Antolin B,et al. A non-invasive lipidomic test accurately discriminates NASH from steatosis and tracks evolution of the disease. Hepatology,2016,64（S1）:559A.
[19] Loomba R,Seguritan V,Li WZ,et al. Novel gut-microbiota based metagenomic signature for the non-invasive detection of advanced fibrosis in nonalcoholic fatty liver disease:A prospective study. Hepatology,2016,64（S1）:70A.
[20] Kawaguchi T,Hashida R,Ueno T,et al. What is the optimal exercise regimen for patients with NAFLD:Aerobic or resistance exercise Hepatology,2016,64 （S1）:565A.
[21] Hayashi M,Takahashi A,Imaizumi H,et al. Simple resistance exercise for 24 weeks decreases alanine aminotransferase levels in patients with non-alcoholic fatty liver disease. Hepatology,2016,64（S1）:567A.
[22] European Association for the Study of the Liver （EASL）,European Association for the Study of Diabetes （EASD）,European Association for the Study of Obesity（EASO）. EASL EASD EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol,2016,64（6）:1388-1402.
[23] Traussnigg S,Kienbacher C,Halilbasic E,et al. Efficacy and safety of the non-steroidal farnesoid X receptor agonist PX-104 in patients with non-alcoholic fatty liver disease（NAFLD）. Hepatology,2016,64（S1）:536A.
[24] Baribault H,Chao JH,Kozuka K,et al. A non-bile acid intestine-selective FXR agonist reducesliver steatosis in mice. Hepatology,2016,64（S1）:558A.
[25] Hameed B,Terrault N,Loomba R,et al. Subgroup analysis comparing obeticholic acid versus placebo for fibrosis improvement:a post-hoc analysis of the FLINT trial. Hepatology,2016,64（S1）:541A.
[26] Wilkison B,Cheatham B,Walker S. Remogliflozin etabonate reduces FIB-4 and NAFLD fibrosis scores in type 2 diabetic subjects. Hepatology,2016,64（S1）:548A.
[27] Ohki T,Kondo M,Kurosaki S,et al. SGLT-2 inhibitors improved liver inflammation and fibrosis of NAFLD patients with type 2 diabetes mellitus with a favorable effect of weight reduction. Hepatology,2016,64（S1）:582A.
[28] Oscarsson J,Kvarnstrom M,Zeneca A,et al. Effects of dapagliflozin,a sodium-glucose co-transporter 2 inhibitor,and free omega-3 carboxylic acids on liver steatosis and hepatocyte damage biomarkers in type 2 diabetes patients with non-alcoholic fatty liver disease. Hepatology,2016,64（S1）:554A.
[29] Nguyen V,Li JW,Cordero P,et al. Intra-gastric balloon （IGB）: an endoscopic treatment option for obesity and NAFLD. Hepatology,2016,64 （S1）:567A. |
